{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T10:52:55Z","timestamp":1782298375145,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82371413"],"award-info":[{"award-number":["82371413"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s00415-025-13476-4","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T05:34:55Z","timestamp":1761716095000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Association between antibody status and exacerbation in patients with myasthenia gravis who achieved minimal manifestation or better status"],"prefix":"10.1007","volume":"272","author":[{"given":"Yi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haobin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8690-2544","authenticated-orcid":false,"given":"Huan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"13476_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112235","volume":"10","author":"L Dresser","year":"2021","unstructured":"Dresser L, Wlodarski R, Rezania K, Soliven B (2021) Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. J Clin Med 10:2235","journal-title":"J Clin Med"},{"key":"13476_CR2","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14:1023\u20131036","journal-title":"Lancet Neurol"},{"key":"13476_CR3","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","volume":"12","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE, Skeie GO, Romi F, Lazaridis K, Zisimopoulou P, Tzartos S (2016) Myasthenia gravis - autoantibody characteristics and their implications for therapy. Nat Rev Neurol 12:259\u2013268","journal-title":"Nat Rev Neurol"},{"key":"13476_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/mus.27832","volume":"68","author":"B Claytor","year":"2023","unstructured":"Claytor B, Cho SM, Li Y (2023) Myasthenic crisis. Muscle Nerve 68:8\u201319","journal-title":"Muscle Nerve"},{"key":"13476_CR5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","volume":"37","author":"D Grob","year":"2008","unstructured":"Grob D, Brunner N, Namba T, Pagala M (2008) Lifetime course of myasthenia gravis. Muscle Nerve 37:141\u2013149","journal-title":"Muscle Nerve"},{"key":"13476_CR6","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1212\/WNL.0b013e31827b907b","volume":"80","author":"F Baggi","year":"2013","unstructured":"Baggi F, Andreetta F, Maggi L et al (2013) Complete stable remission and autoantibody specificity in myasthenia gravis. Neurology 80:188\u2013195","journal-title":"Neurology"},{"key":"13476_CR7","doi-asserted-by":"publisher","first-page":"175628642210805","DOI":"10.1177\/17562864221080520","volume":"15","author":"Y Li","year":"2022","unstructured":"Li Y, Yang S, Dong X et al (2022) Factors affecting minimal manifestation status induction in myasthenia gravis. Ther Adv Neurol Disord 15:17562864221080520","journal-title":"Ther Adv Neurol Disord"},{"key":"13476_CR8","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12883-016-0756-3","volume":"16","author":"T Akaishi","year":"2016","unstructured":"Akaishi T, Suzuki Y, Imai T et al (2016) Response to treatment of myasthenia gravis according to clinical subtype. BMC Neurol 16:225","journal-title":"BMC Neurol"},{"key":"13476_CR9","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M et al (2016) International consensus guidance for management of myasthenia gravis: executive summary. Neurology 87:419\u2013425","journal-title":"Neurology"},{"key":"13476_CR10","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1111\/cns.13468","volume":"26","author":"C Zhang","year":"2020","unstructured":"Zhang C, Bu B, Yang H et al (2020) Immunotherapy choice and maintenance for generalized myasthenia gravis in China. CNS Neurosci Ther 26:1241\u20131254","journal-title":"CNS Neurosci Ther"},{"key":"13476_CR11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/mus.25052","volume":"54","author":"A Gupta","year":"2016","unstructured":"Gupta A, Goyal V, Srivastava AK, Shukla G, Behari M (2016) Remission and relapse of myasthenia gravis on long-term azathioprine: an ambispective study. Muscle Nerve 54:405\u2013412","journal-title":"Muscle Nerve"},{"key":"13476_CR12","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1212\/WNL.0000000000002405","volume":"86","author":"B Oskarsson","year":"2016","unstructured":"Oskarsson B, Rocke DM, Dengel K, Richman DP (2016) Myasthenia gravis exacerbation after discontinuing mycophenolate: a single-center cohort study. Neurology 86:1159\u20131163","journal-title":"Neurology"},{"key":"13476_CR13","doi-asserted-by":"publisher","first-page":"1177249","DOI":"10.3389\/fimmu.2023.1177249","volume":"14","author":"Z Bi","year":"2023","unstructured":"Bi Z, Zhan J, Zhang Q et al (2023) Clinical and immune-related factors associated with exacerbation in adults with well-controlled generalized myasthenia gravis. Front Immunol 14:1177249","journal-title":"Front Immunol"},{"key":"13476_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.816243","volume":"13","author":"S Su","year":"2022","unstructured":"Su S, Lei L, Fan Z et al (2022) Clinical predictors of relapse in a cohort of steroid-treated patients with well-controlled myasthenia gravis. Front Neurol 13:816243","journal-title":"Front Neurol"},{"key":"13476_CR15","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/ana.410150316","volume":"15","author":"RM Pascuzzi","year":"1984","unstructured":"Pascuzzi RM, Coslett HB, Johns TR (1984) Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 15:291\u2013298","journal-title":"Ann Neurol"},{"key":"13476_CR16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/nyas.13544","volume":"1413","author":"H Murai","year":"2018","unstructured":"Murai H, Utsugisawa K, Nagane Y, Suzuki S, Imai T, Motomura M (2018) Rationale for the clinical guidelines for myasthenia gravis in Japan. Ann N Y Acad Sci 1413:35\u201340","journal-title":"Ann N Y Acad Sci"},{"key":"13476_CR17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","volume":"55","author":"A Jaretzki 3rd","year":"2000","unstructured":"Jaretzki A 3rd, Barohn RJ, Ernstoff RM et al (2000) Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the myasthenia gravis foundation of America. Neurology 55:16\u201323","journal-title":"Neurology"},{"key":"13476_CR18","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/mus.25205","volume":"54","author":"JB Andersen","year":"2016","unstructured":"Andersen JB, Gilhus NE, Sanders DB (2016) Factors affecting outcome in myasthenia gravis. Muscle Nerve 54:1041\u20131049","journal-title":"Muscle Nerve"},{"key":"13476_CR19","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1002\/mus.26850","volume":"61","author":"MK Hehir","year":"2020","unstructured":"Hehir MK, Punga AR, Ciafaloni E (2020) Myasthenia gravis patient and physician opinions about immunosuppressant reduction. Muscle Nerve 61:767\u2013772","journal-title":"Muscle Nerve"},{"key":"13476_CR20","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G et al (2021) International consensus guidance for management of myasthenia gravis: 2020 update. Neurology 96:114\u2013122","journal-title":"Neurology"},{"key":"13476_CR21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0303-8467(87)80046-X","volume":"89","author":"HJ Scherpbier","year":"1987","unstructured":"Scherpbier HJ, Oosterhuis HJ (1987) Factors influencing the relapse risk at steroid dose reduction in myasthenia gravis. Clin Neurol Neurosurg 89:145\u2013150","journal-title":"Clin Neurol Neurosurg"},{"key":"13476_CR22","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1186\/s13023-024-03466-6","volume":"19","author":"M Su","year":"2024","unstructured":"Su M, Liu X, Wu Z et al (2024) Nomogram for predicting pregnancy-related relapse of myasthenia gravis. Orphanet J Rare Dis 19:452","journal-title":"Orphanet J Rare Dis"},{"key":"13476_CR23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12883-017-0857-7","volume":"17","author":"L Wang","year":"2017","unstructured":"Wang L, Zhang Y, He M (2017) Clinical predictors for the prognosis of myasthenia gravis. BMC Neurol 17:77","journal-title":"BMC Neurol"},{"key":"13476_CR24","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s12883-020-01802-4","volume":"20","author":"A Bogdan","year":"2020","unstructured":"Bogdan A, Barnett C, Ali A et al (2020) Prospective study of stress, depression and personality in myasthenia gravis relapses. BMC Neurol 20:261","journal-title":"BMC Neurol"},{"key":"13476_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16022","volume":"31","author":"R Martinez-Harms","year":"2024","unstructured":"Martinez-Harms R, Barnett C, Alcantara M, Bril V (2024) Clinical characteristics and treatment outcomes in patients with double-seronegative myasthenia gravis. Eur J Neurol 31:e16022","journal-title":"Eur J Neurol"},{"key":"13476_CR26","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/j.1468-1331.2005.01137.x","volume":"12","author":"F Romi","year":"2005","unstructured":"Romi F, Aarli JA, Gilhus NE (2005) Seronegative myasthenia gravis: disease severity and prognosis. Eur J Neurol 12:413\u2013418","journal-title":"Eur J Neurol"},{"key":"13476_CR27","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1007\/s00417-024-06425-w","volume":"262","author":"T Goto","year":"2024","unstructured":"Goto T, Kimura A, Masuda A, Mochizuki Y, Gomi F (2024) Clinical features of double seronegative ocular myasthenia gravis. Graefes Arch Clin Exp Ophthalmol 262:2617\u20132623","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"13476_CR28","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1001\/jamaneurol.2016.2032","volume":"73","author":"E Cort\u00e9s-Vicente","year":"2016","unstructured":"Cort\u00e9s-Vicente E, Gallardo E, Mart\u00ednez M\u00c1 et al (2016) Clinical characteristics of patients with double-seronegative myasthenia gravis and antibodies to cortactin. JAMA Neurol 73:1099\u20131104","journal-title":"JAMA Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13476-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13476-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13476-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T14:00:58Z","timestamp":1763128858000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13476-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["13476"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13476-4","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"25 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was approved by the Medical Ethics Committee of the Hunan Medical Science Research Institute of Xiangya Hospital (Ethical Approval Document No: 202206153). All participants were informed and signed the consent form for the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"736"}}